OMERS ADMINISTRATION Corp Buys Shares of 18,100 Genmab A/S (NASDAQ:GMAB)

OMERS ADMINISTRATION Corp acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 18,100 shares of the company's stock, valued at approximately $378,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GMAB. Laird Norton Wetherby Wealth Management LLC raised its stake in Genmab A/S by 17.3% during the 4th quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company's stock valued at $286,000 after buying an additional 2,023 shares during the last quarter. Hudson Bay Capital Management LP raised its stake in Genmab A/S by 103.8% during the 4th quarter. Hudson Bay Capital Management LP now owns 540,000 shares of the company's stock valued at $11,270,000 after buying an additional 275,000 shares during the last quarter. Graham Capital Management L.P. raised its stake in Genmab A/S by 38.2% during the 4th quarter. Graham Capital Management L.P. now owns 55,417 shares of the company's stock valued at $1,157,000 after buying an additional 15,321 shares during the last quarter. Deep Track Capital LP purchased a new stake in Genmab A/S during the 4th quarter valued at $41,740,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in Genmab A/S during the 4th quarter valued at $12,360,000. 7.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on GMAB shares. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Finally, BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Stock Performance

Shares of GMAB traded down $0.22 during midday trading on Friday, hitting $20.81. 1,247,688 shares of the company traded hands, compared to its average volume of 1,131,782. The firm has a 50 day moving average of $19.77 and a 200-day moving average of $20.67. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $28.96. The stock has a market cap of $13.34 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.